Editas Medicine, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.editasmedicine.com

Moat Score
Safety Score

Market Cap $109.90M
PE -0
Debt $62.43M
Cash $135.42M
EV $36.92M
FCF -$219.11M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$237.09M
EBIT	-$251.15M
ROE	-177%
ROA	-74%
FCF	-$219.11M
Equity	$134.27M
Growth Stability	1
PE	-0.46
PB	0.82
P/FCF	-0.5
P/S	3.4
Price/Cash	1.23
Debt/Equity	0.46
Debt/FCF	-0.28
Net Margins	-734%
Op. Margins	-777%
Sales Growth YoY	-49%
Sales Growth QoQ	50K%
Sales CAGR	10%
Equity CAGR	8%
Earnings Growth YoY	141%

Earnings Growth QoQ	-27%
Sales CAGR 5Y	-2%
Equity CAGR 5Y	-16%
Earnings CAGR 3Y	43%
Sales CAGR 3Y	43%
Equity CAGR 3Y	-33%
Market Cap	$109.90M
Revenue	$32.31M
Assets	$341.59M
Total Debt	$62.43M
Cash	$135.42M
Shares Outstanding	82.32M
EV	36.92M
Moat Score	0%
Safety Score	64%
Working Capital	212.09M
Current Ratio	3.75
Shares Growth 3y	9%
Equity Growth QoQ	-24%
Equity Growth YoY	-62%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.

SEC Filings

Direct access to Editas Medicine, Inc. (EDIT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Editas Medicine, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Editas Medicine, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Editas Medicine, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Editas Medicine, Inc..

Years

Calculation mode

= -$2.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$219M	-$2.2B
DCF		-$199M	-$181M	-$165M	-$150M	-$136M	-$124M	-$112M	-$102M	-$93M	-$84M	-$845M
Value	-$2.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-2K%	-876%	-344%	-651%	-128%	-754%	-1K%	-196%	-734%	-734%
ROA	-	-42%	-32%	-27%	-28%	-24%	-29%	-44%	-34%	-74%	-74%
ROE	-	-72%	-58%	-47%	-51%	-29%	-35%	-61%	-44%	-177%	-177%

Bad Net Margins (-733.72%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-0	-0.28	-0.28
Debt over Equity	-	-	-	-	-	-	-	-	0	0.46	0.46
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.28)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.46)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	127%	133%	-36%	342%	-72%	-23%	296%	-59%	-2%
Earnings YoY growth	-	33%	24%	-9%	22%	-13%	66%	15%	-30%	55%	-
Equity YoY growth	-	-262%	55%	13%	11%	50%	41%	-35%	-3%	-62%	-16%
FCF YoY growth	-	682%	-79%	340%	-7%	299%	-8%	6%	-25%	60%	-